Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rescigno

Showing results (631-640 of 1,117) with videos related to

Pageof 112
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou B Lambros, George Seed, Semini Sumanasuriya, et al.
The Oncologist|August 1, 2020
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise CentersLucia Nappi, Margaret Ottaviano, Pasquale Rescigno, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Elife|August 23, 2017
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancerLaura Cato, Antje Neeb, Adam Sharp, et al.
Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Life (Basel, Switzerland)|January 23, 2024
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA StudyAlfredo Caturano, Raffaele Galiero, Erica Vetrano, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
European Urology|November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
Pageof 112

Showing results (631-640 of 1,117) with videos related to

Sort By:
Pageof 112
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou B Lambros, George Seed, Semini Sumanasuriya, et al.
The Oncologist|August 1, 2020
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise CentersLucia Nappi, Margaret Ottaviano, Pasquale Rescigno, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Elife|August 23, 2017
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancerLaura Cato, Antje Neeb, Adam Sharp, et al.
Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Life (Basel, Switzerland)|January 23, 2024
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA StudyAlfredo Caturano, Raffaele Galiero, Erica Vetrano, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
European Urology|November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
Pageof 112